ARCHIVES

Economic Analysis Finds Erlotinib Marginally Cost-Effective For NSCLC

This article is from The Cancer Letter archive.

Vol. 33 No. 2 | February 26, 2010

Download PDF Visit The Full Archive

Related Articles

Duke recruits Judd Moul as chief of urology.

July 9, 2004

NCI apologize For Mismanagement Of NSABP, Says Fisher Resisted Criticism

April 22, 1994

NIH Limits Salaries On Grants, Contracts ACS Clinical Awards Available For 1995

February 25, 1994

Committee, BSC Recommend Against Continuing Women’s Health Trial; Appeal to NCAB Seen

January 15, 1988

Five Years after Proton Therapy, 75-99% of Men Live Cancer-Free

February 28, 2014

Chabner Object To Yarbro’s Remarks On Federal Role In Clinical Research

April 15, 1983